Soleno Therapeutics (SLNO)
(Delayed Data from NSDQ)
$81.63 USD
-2.49 (-2.96%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $81.63 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SLNO 81.63 -2.49(-2.96%)
Will SLNO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SLNO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLNO
Soleno Therapeutics, Inc. (SLNO) is a Great Momentum Stock: Should You Buy?
Can Soleno Therapeutics (SLNO) Climb 33.11% to Reach the Level Wall Street Analysts Expect?
SLNO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Could Help Soleno Therapeutics (SLNO) Maintain Its Recent Price Strength
Soleno Therapeutics (SLNO) is on the Move, Here's Why the Trend Could be Sustainable
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug
Other News for SLNO
Earnings Scheduled For August 6, 2025
Soleno Therapeutics's Earnings: A Preview
Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2025 Commentary
Janus Henderson Global Life Sciences Fund Q2 2025 Commentary
Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 ...